Wall Street analysts predict that Puma Biotechnology Inc (NASDAQ:PBYI) will announce $69.32 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Puma Biotechnology’s earnings. The lowest sales estimate is $64.63 million and the highest is $74.00 million. The business is expected to report its next earnings report on Wednesday, May 9th.
On average, analysts expect that Puma Biotechnology will report full-year sales of $69.32 million for the current fiscal year, with estimates ranging from $235.00 million to $235.73 million. For the next fiscal year, analysts anticipate that the firm will report sales of $474.61 million per share, with estimates ranging from $427.11 million to $522.10 million. Zacks’ sales averages are an average based on a survey of analysts that follow Puma Biotechnology.
Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings data on Thursday, March 1st. The biopharmaceutical company reported ($1.71) EPS for the quarter, topping analysts’ consensus estimates of ($1.98) by $0.27. The company had revenue of $21.60 million for the quarter, compared to analyst estimates of $20.83 million. During the same period last year, the firm earned ($1.22) earnings per share.
Shares of Puma Biotechnology stock opened at $67.10 on Tuesday. The company has a quick ratio of 1.79, a current ratio of 1.82 and a debt-to-equity ratio of 0.91. Puma Biotechnology has a 12 month low of $28.35 and a 12 month high of $136.90. The firm has a market cap of $2,495.16, a P/E ratio of -8.55 and a beta of 0.15.
In other Puma Biotechnology news, SVP Richard Paul Bryce sold 1,860 shares of the business’s stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $92.75, for a total value of $172,515.00. Following the completion of the transaction, the senior vice president now directly owns 25,379 shares of the company’s stock, valued at $2,353,902.25. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Alan H. Auerbach sold 10,692 shares of the business’s stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $92.75, for a total value of $991,683.00. Following the completion of the transaction, the insider now directly owns 4,155,931 shares of the company’s stock, valued at $385,462,600.25. The disclosure for this sale can be found here. 21.10% of the stock is currently owned by insiders.
Large investors have recently bought and sold shares of the business. First Republic Investment Management Inc. acquired a new position in Puma Biotechnology in the fourth quarter valued at about $208,000. Sei Investments Co. acquired a new position in shares of Puma Biotechnology during the third quarter worth about $256,000. Jafra Capital Management LP acquired a new position in shares of Puma Biotechnology during the fourth quarter worth about $257,000. Clear Harbor Asset Management LLC acquired a new position in shares of Puma Biotechnology during the fourth quarter worth about $288,000. Finally, Xact Kapitalforvaltning AB acquired a new position in shares of Puma Biotechnology during the fourth quarter worth about $292,000. 95.95% of the stock is owned by hedge funds and other institutional investors.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.